Always enjoy your posts. However, being true to my nom de plume, I have to disagree with your assessment on a buy out in 2018. My response to such a date is - WHY BOTHER? If Elite were to arrive at that year and they have hit the Nasdaq, filed and had approved multiple ADFs, increased the number of generics and their sales (however, small), and even reduced R&D costs associated with fewer trials, I would seriously argue they would have a firm capable of achieving the heights suggested by those using the seemingly wildly enthusiastic comparisons to Pharmacyclics and Jazz. Realistically, when there is the potential for their tech platform that would enable multiple filings, the math becomes compelling for continuing on their current path . How much so? That answer is complex...